In recent years, epidermal growth factor receptor (EGFR) mutations and anaplastic large-cell lymphoma kinase (ALK) rearrangements are now routine biomarkers that have been incorporated into the practice of managing non-small-cell lung cancer (NSCLC). This evidence concerns the gene ALK and non-small cell lung carcinoma.